|**Guru**|**Karshni Trust**|**Karshni Trust**||**1176011**||
|---|---|---|---|---|---|
||**Receipts andpayments accounts**||||**CC16a**|
|**For**|**the period**<br>**from**|01/04/2024|**To**|31/03/2025||




## **Section A Receipts and payments** 

|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest**<br>**£**<br>**141**<br>**12,000**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**12,141**<br>**-**<br>**-**<br>**-**<br>**12,141**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> **-**<br>**24,000**<br>**-**<br> **24,000**<br>**24,000**<br>**-               11,859**<br>**-**<br>**16,127**<br>**4,268**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Total funds**<br>**to the nearest £**<br>**141**<br>**12,000**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**12,141**<br>**-**<br>**-**<br>**-**<br>**12,141**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**24,000**<br>**-**<br>**24,000**<br>**24,000**<br>**-               11,859**|**Total funds**<br>**to the nearest £**<br>**141**<br>**12,000**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**12,141**<br>**-**<br>**-**<br>**-**<br>**12,141**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**24,000**<br>**-**<br>**24,000**<br>**24,000**<br>**-               11,859**|**Last year**<br>**to the nearest £**|
|---|---|---|---|---|---|---|
|Interest on Deposit Account|**141**|||||**12,000**|
|Donations,legacies andgrants|**12,000**|||||**116**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|**12,141**|||||**12,116**|
||||||||
|**A2 Asset and investment sales,**<br>**(see table).**|||||||
||**-**||||||
||**-**|||||**-**|
|**_Sub total_**|**-**|||||**-**|
|**_Total receipts_**<br>**A3 Payments**|||||||
|||||||**12,116**|
||||||||
|Cost of Charitable Activities|**-**|||||**-**|
||**-**||||||
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_ **|**-**|||||**-**|
||||||||
|**A4 Asset and investment**<br>**purchases, (see table)**|||||||
|**Loan made to Raman Pharma**|**24,000**||||||
||**-**||||||
|**_Sub total_ **|**24,000**|||||**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**|||||||
|||||||**-**|
||||||||
||**-               11,859**|**-**|**-**|**-               11,859**||**12,116**|
||**-**|**-**|**-**|**-**||**-**|
||**16,127**|**-**|**-**|**16,127**||**4,011**|
||**4,268**|**-**|**-**|**4,268**||**16,127**|



CCXX R1 accounts (SS) 

31/01/2026 

1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on<br>behalf of all the trustees<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B5 Liabilities**<br>**B3 Investment assets**|Signature<br>**Details**<br>**Details**<br>Deposit Account<br>**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>**Details**<br>Investment to Raman Pharma|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**4,268**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**4,268**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**24000**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Dhruv Raheja|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
|||Dhruv Raheja|16/04/2025|
|||||



CCXX R2 accounts (SS) 

31/01/2026 

2 

